• TRM (USD/COP)COP 3,461.92 +1.37% +COP 46.82Colombia's official exchange rate (Financial Superintendence), valid Nov 21 to Nov 23
  • EuroCOP 3,804.64 +1.37% +COP 51.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote
  • Mexican pesoCOP 181.56 +1.37% +COP 2.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote

HC Wainwright keeps Palvella Therapeutics at "buy" with $246 price target

FinanceInternationalTradingViewAI summary
Image: TradingView

HC Wainwright & Co. maintained its "buy" rating and $246 price target for Palvella Therapeutics. That target implies 68.8% upside from the November 19 close of $145.77. The four most recent analyst notes on the company over the past 30 days set price targets between $228 and $243.

In 25 seconds

  • HC Wainwright & Co. reiterates its "buy" rating for Palvella Therapeutics.
  • The price target remains at $246 per share.
  • The target implies 68.8% upside from the November 19 close of $145.77.
Read the full story at TradingView

IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.

Comments

Be respectful. Comments reported by several people are hidden until a moderator reviews them.

You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.

    Keep reading